In lupus tumidus, the extent and severity of cutaneous involvement directly shape treatment strategy. When lesions are severe or widely disseminated, first-line management requires a combination approach that goes beyond localised topical care.

Clinical Scenario

This first-line protocol applies to patients with lupus tumidus presenting with severe or disseminated cutaneous lupus erythematosus skin lesions — a presentation where systemic therapy is indicated from the outset, supported by evidence recommending antimalarial drugs as first-line treatment in all CLE patients with severe and disseminated skin lesions, particularly those at risk of scarring.

Treatment Approach (Overview)

Management combines topical agents applied directly to skin lesions with systemic antimalarial therapy; in severe presentations, a time-limited course of systemic glucocorticoids is added alongside — the complete regimen, with full agent selection and sequencing, is in the structured protocol.

References

DOI: 10.1111/ddg.14491

Antimalarial drugs are recommended as first-line treatments, also for long-term therapy, in all CLE patients with severe and disseminated skin lesions; in particular for patients with a risk of scarring.
For severe or disseminated CLE lesions, systemic glucocorticoids are recommended as first-line treatment in addition to antimalarial drugs, for a limited period of time.
Class 2-4 topical glucocorticoids are the treatment of choice for cutaneous lupus erythematosus (CLE).
Topical calcineurin inhibitors are recommended predominantly for treating facial lesions, but also as an alternative to topical glucocorticoids.
Tacrolimus 0.1 % ointment was most effective in patients with lupus erythematosus tumidus (LET), followed by SCLE patients.
Systemic glucocorticoids should be tapered off as soon as possible.

View source ↗

Treatment of Lupus Tumidus with Severe or Disseminated Cutaneous Lupus Erythematosus Skin Lesions

References